CVS Health Corporation (NYSE:CVS) finished Wednesday with a subtraction of -$0.65 to close at $66.40, a downside of -0.97 percent. An average of 16,613,920 shares of common stock have been traded in the last five days. There was a fall of -$6.32 in the past week, and it reached a new high 7 times over the past 12 months. The last 20 days have seen an average of 10,541,905 shares traded, while the 50-day average volume stands at 10,113,370.
CVS stock has decreased by -12.24% in the last month. The company shares reached their 1-month lowest point of $64.62 on 08/17/23. With the stock rallying to its 52-week high on 01/04/23, shares of the company touched a low of $64.62 and a high of $104.83 in 52 weeks. It has reached a new high 2 times so far this year and lost -28.75% or -$26.79 in price. In spite of this, the price is down -36.66% from the 52-week high.
Insider Transactions
CVS stock investors should be aware that CVS Health Corporation (CVS) stock had its last reported insider trading activity 21 days ago on Aug 03. In this transaction, the insider spent $1,930,004. EVP & General Counsel, Moriarty Thomas M, disposed of 137,466 shares at a price of $98.36 on Dec 15. The insider now owns more than $13,521,180 worth of shares.
Valuation Metrics
CVS Health Corporation (CVS) has a trailing price-to-earnings (P/E) ratio of 29.15. The stock’s beta is 0.62. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.25, the price-to-book (PB) ratio at 1.17, and the price-to-cash flow ratio at 4.82.
The company has a payout ratio of 109.50%. The company’s most recent quarterly dividend payment was $0.6050 a share, without any change from last year. Its latest increase dividend $0.0550 reported on Thursday December 15 2022.
Financial Health
The quick ratio of CVS Health Corporation for the three months ended June 29 was 0.60, and the current ratio was 0.90, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.84 and a total debt to equity ratio of 0.88 for the quarter ending June 29. CVS Health Corporation’s EBITDA margin for the year ending June 29 is 6.40%, while its operating margin for the same period stands at 1.90%. Its gross profit as reported stood at $125.58 billion compared to revenue of $322.47 billion.
Earnings Surprise
For the three-month period that ended June 29, CVS Health Corporation had $61.42 billion in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $1.9 billion in the quarter, while revenues of $2.14 billion were shrunk -55.23%. The analyst consensus anticipated CVS Health Corporation’s latest quarter earnings to come in at $2.11 per share, but it turned out to be $2.21, a 4.70% surprise. For the quarter, EBITDA amounted to $4.34 billion. Shareholders own equity worth $1.28 billion.
Technical Picture
From a technical analysis perspective, let’s take a brief look at CVS Health Corporation (CVS) price momentum. RSI 9-day as of the close on 23 August was 22.07%, suggesting the stock is oversold, with historical volatility in this time frame at 41.48%.
As of today, CVS’s price is $66.83 -8.69% or -$6.32 from its 5-day moving average. CVS is currently trading -11.58% lower than its 20-day SMA and -11.11% lower than its 100-day SMA. However, the stock’s current price level is -7.13% below the SMA50 and -32.11% below the SMA200.
The stochastic %K and %D were 18.67% and 18.46%, respectively, and the average true range (ATR) was 1.80. With the 14-day stochastic at 16.59% and the average true range at 1.74, the RSI (14) stands at 29.74%. The stock has reached -3.09 on the 9-day MACD Oscillator while the 14-day reading was at -4.50.
Analyst Ratings
Edward Jones downgraded CVS Health Corporation (NYSE: CVS) to a a Hold rating in its most recent analyst report. Previously, the stock was rated as a Buy. The consensus rating for CVS Health Corporation (CVS) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell CVS, while 8 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 2 analysts, while 17 others rate it as a “buy”.
What is CVS’s price target for the next 12 months?
Analysts predict a range of price targets between $76.00 and $110.00, with a median target of $90.45. Taking a look at these predictions, the average price target given by analysts for CVS Health Corporation (CVS) stock is $92.16.
